Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tevogen Bio Holdings Inc. - Warrant
(NQ:
TVGNW
)
0.0449
+0.0003 (+0.67%)
Streaming Delayed Price
Updated: 3:20 PM EST, Dec 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
91,799
Open
0.0411
Bid (Size)
0.0412 (800)
Ask (Size)
0.0444 (1,000)
Prev. Close
0.0446
Today's Range
0.0411 - 0.0450
52wk Range
0.0360 - 0.1218
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
December 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
December 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Performance
YTD
-25.2%
-25.2%
1 Month
-5.3%
-5.3%
3 Month
-25.9%
-25.9%
6 Month
-28.8%
-28.8%
1 Year
+6.9%
+6.9%
More News
Read More
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
November 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
November 05, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
These stocks are moving in today's after hours session
↗
November 03, 2025
Via
Chartmill
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
November 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Gapping stocks in Monday's session
↗
November 03, 2025
Via
Chartmill
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
October 29, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
October 15, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
September 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
September 23, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
September 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 08, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
September 04, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
September 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
August 27, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
August 26, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
August 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
August 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
August 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
August 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Frequently Asked Questions
Is Tevogen Bio Holdings Inc. - Warrant publicly traded?
Yes, Tevogen Bio Holdings Inc. - Warrant is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Warrant trade on?
Tevogen Bio Holdings Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Warrant?
The ticker symbol for Tevogen Bio Holdings Inc. - Warrant is TVGNW on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Warrant?
The current price of Tevogen Bio Holdings Inc. - Warrant is 0.0449
When was Tevogen Bio Holdings Inc. - Warrant last traded?
The last trade of Tevogen Bio Holdings Inc. - Warrant was at 12/12/25 03:20 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today